5243722025-01-012025-03-315243722025-03-315243722024-03-315243722024-04-012025-03-315243722025-01-012025-03-31in-capmkt:OtherExpenses1Member5243722024-04-012025-03-31in-capmkt:OtherExpenses1Member5243722025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15243722024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15243722025-01-012025-03-31AuditorDomain15243722025-01-012025-03-31in-capmkt:AuditedMember5243722025-03-31in-capmkt:AuditedMember5243722025-01-012025-03-31in-capmkt:AdjustedMember5243722025-03-31in-capmkt:AdjustedMember5243722025-01-012025-03-31AuditQualification1iso4217:INRiso4217:INRxbrli:shares524372ORCHPHARMANOTLISTEDINE191A01027ORCHID PHARMA LIMITEDMain BoardEquity2024-04-012025-03-312025-05-262025-05-20INRLakhsQuarterlyFourth quarterSingle segmentPharmaceuticals2025-05-2612:00:002025-05-2615:35:00trueCash Flow IndirectStatement on impact of audit qualification2025-01-012025-03-31AuditedConsolidated2374787000389720002413759000136944600012440000-17240002224240003915000088717000492365000222281800019094100001909410000-394000-39400001913350000003161100022294600016675000239621000507191000104.44.4004.44.41. The above results for the quarter and year ended March 31 , 2025 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on May 26, 2025. The statutory auditors of the company have expressed an unmodified opinion on the audited Standalone results and a modified opinion on the audit of the Consolidated results. <BR> 2.The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards Ind AS as prescribed under Section 133 of the Companies Act, 2013, read with the Companies Indian Accounting Standards Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable. <BR> 3. 99,02,705 fully paid up Equity Shares of face value INR10 each of the Company was allotted on 27th June 2023 by way of Qualified Institutional Placement ,QIP, whereby proceeds of Rs.39180 Lakhs ,Net of Share issue expenses, was raised. <BR> As on March 31, 2025, the entire net Proceeds of Rs.39180 Lakhs was received by the Company under the QIP and the Statement of Net funds raised and its utilisation is furnished below : <BR> Statement of QIP Net Funds raised and utilisation <BR> Particulars Amount as stated in Total amount utilised Balance amount as on Remarks <BR> the Offer Document upto March 31, 2025 on March 31, 2025 kept <BR> Rs. In Lakhs Rs. In Lakhs in Fixed Deposits in lakhs <BR> 1)Investment in OBPL, subsidiary, <BR> for setting up Jammu <BR> Manufacturing Facility 9000 4416 4584 <BR> 2)Repayment/prepayment, in <BR> full or in part, of certain <BR> outstanding borrowings <BR> availed by the company 14100 14100 - <BR> 3)Funding capital expenditure <BR> requirements for setting up a <BR> new block at the API facility <BR> of the Company in Alathur, <BR> Tamil Nadu 9982 36 9946 <BR> 4)General corporate purposes 6098 6372 0 _ <BR> Total 39180 24924 14530 <BR> As per the QIP offer Document the amount allocated for General Corporate Purpose, GCP, was Rs. 6098 Lakh which was based on then proposed net proceeds after issue expenses being Rs.39180 Lakh. However, net proceeds transferred to Monitoring Account was Rs. 39454 Lakh as against the proposed net Proceeds of Rs. 39180 Lakh, therefore the Surplus amount of Rs. 274 Lakh has been included in the GCP balance as on March 31, 2025. <BR> Balance amount excludes the interest earned on the unutilized QIP funds kept in fixed deposits. <BR> 4. The operations of the Company falls under a single operating segment i.e., Pharmaceuticals in accordance with Ind AS 108, Operating Segments, and hence no reporting as per Ind AS 108 is applicable. <BR> 5. The figures for the quarters ended 31st March, 2025 and 31st March, 2024 are the balancing figures between audited figures in respect of the full financial year and year to date figures up to the third quarter of the relevant financial years which were subjected to limited review. <BR> 6. The Company has submitted a petition with the Honourable National Company Law Tribunal, Chennai bench, for amalgamation of its Holding Company Dhanuka Laboratories Limited, the Amalgamating Company, with the <BR> Company in compliance with Section 230 to 232 and other relevant provisions of the Companies Act 2013 . The scheme of amalgamation had been approved by the Board of Directors of the respective Companies. Further, <BR> in compliance with the SEBI Listing Regulations and Master Circulars issued thereon, the Company has obtained Observation Letter from the BSE Limited and National Stock Exchange of India Limited, stock exchanges, <BR> giving No objection to the said amalgamation. Further, the Honourable NCLT have pronounced the order dated 29th April, 2025 , inter alia, issuing directions for convening meetings of equity shareholders of the Company and unsecured creditors of both Companies and dispensed off the meetings of equity shareholders of the Amalgamating Company and secured creditors of both the Companies, considering their respective consents to the Scheme already submitted before the Honourable NCLT. The management of the respective Companies are taking steps to comply with the said Order. <BR> <BR> 7. Figures of the previous period have been regroupted or reclassified or restated wherever considered necessary.2024-04-012025-03-31AuditedConsolidated92192590002747470009494006000585460600026131000-4385110008636060001454010003454580001741667000853835800095564800009556480000-1935000-1935000095758300000038985000996568000-751300098905500050719100010019.6519.650019.6519.65Other Expenses492365000Other Expenses174166700063158540006448930000112530000162236000004967060000042698000539404000513015000618319000880497400032637150000241832100021106800015852570000304360004245082000277410005376350008074173000001687914700050719100012165663000126728540000126728540001316358000000013163580003387200000367000135059700042603300011023400021106870002220921000026469540001850820002366000000285569600000420629300016879147000145401000-621454000-4906600006841100045219000319800016939000000-6782300000345458000003245000000-58488000000000000-5813490003742990000172774000093740000192151000000000000150108000000000000000000001044385000018738600000-269309000000000002855580002207000003113400000252217000175059000017505900036009000211068000Items that will not be classified to profit or loss1667500016675000Items that will not be classified to profit or loss-7513000-7513000000016675000-7513000AuditedQualified opinionSinghi and Co.true2025-08-31953299100095329910008536423000853642300099656800099656800019.6519.651687914700016879147000420629300042062930001267285400012672854000The Consolidated Financial Statements for the year ended March 31, 2025 include the <br></br> financial statements for the year ended March 31, 2025, of the following subsidiary <br></br> compames: <br></br> (i) Orchid Pharmaceuticals Inc., USA <br></br> (ii) Bexel Pharmaceuticals Inc., USA <br></br> (iii)Orchid Pharmaceuticals SA (Proprietary) Limited, South Africa (Upto 31 sl <br></br> January 2024) <br></br> (iv) Diakron Pharmaceuticals, Inc. USA <br></br> <br></br> We did not audit the financial statements of the above subsidiaries whose financial statements <br></br> reflect total Assets of RS.349.09 Lakhs as at March 31, 2025, total revenue from operations of Rs. <br></br> Nil, total comprehensive income after tax of Rs.(-) 634.35 Lakhs for the year ended March 31,2025 <br></br> and net cash flows amounting to Rs. Nil for the year ended on that date as considered in the <br></br> consolidated financial statements. <br></br> The financial statements of the above subsidiaries are unaudited and have been furnished to us <br></br> by the management and our opinion on the Consolidated financial statements, in so far as it relates <br></br> to the amounts and disclosures included in respect of the subsidiaries and associate, is based <br></br> solely on such unaudited financial statements. Accordingly, we do not express any opinion on the <br></br> completeness and true and fair view of the financial statements, including adjustments, if any, <br></br> required on the carrying amount of assets and liabilities of the above subsidiaries and associate <br></br> and foreign currency translation reserve as at March 31,2025 included in the consolidated financial <br></br> statements. This has also been qualified in the Limited Review reports of the earlier quarters and <br></br> audit reports of the earlier years, audited by the predecessor auditor.Qualified opinionRepetitiveNot ApplicableNot ApplicableThe subsidiaries of the Company are located in USA and South Africa. Audit is not compulsory for companies in USA, if they are not publicly traded Orchid Pharmaceuticals SA, Proprietary, Limited, South Africa have been closed till January 2024. Orchid Pharmaceauticals Inc is now audited upto March 31, 2023. Further transactions in majority of the above subsidiaries are either Nil or very minimum. Hence the management has used unaudited <br></br> financials for the purpose of consolidation.Refer, Basis for Qualified Opinion, in our audit report. <br></br> Manish DhanukaSunil Kumar GuptaManoj GoyalSinghi and Co.Gurugram2025-05-26